Sign in
Not yet taking people in United StatesPhase 2

A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Ann Arbor, Boston, Houston, Kansas City, and Philadelphia, United StatesSee the 5 sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
55 people, planned
Starts
27 Apr 2027
Expected to end
31 Jul 2032
Type of study
Interventional
Treatments tested
  • Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
  • Biopsy Procedure
  • Biospecimen Collection
  • Colonoscopy
  • MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
  • Sigmoidoscopy
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Participants must be 18 years or older
  • Participants must be diagnosed with Lynch syndrome. They must be documented carriers (or obligate carriers by pedigree) of a germline mutation in MMR genes (MLH1, MSH2/EPCAM, MSH6, or PMS2) that is deleterious/pathogenic or suspected to be deleterious/pathogenic (known or predicted to be detrimental/loss of function, respectively). The mutation must have been identified through a Clinical Laboratory Improvement Act (CLIA)-approved laboratory setting or an equivalent international agency. Final determination of eligibility for any discordant results in pathogenicity of the mutation will be determined by the study investigator. A formal eligibility exception in those instances will not be required as long as approval by the overall study principal investigator (PI) has been granted and documented
  • Participants must have at least one colorectal lesion that is greater than or equal to 5 mm to less than or equal to 15 mm in diameter (including lesions measuring exactly 5 mm or 15 mm) and narrow-band imaging (NBI) international colorectal endoscopic (NICE) Type II identified during the baseline lower GI endoscopy
  • Participants must have documented history of tubular adenomas and/or tubulovillous adenomas and/or advanced adenomas in the previous five years
  • Participants must have no evidence of active or recurrent invasive cancer for 6 months prior to screening
  • Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy, or radiation)
  • Participants must have endoscopically accessible distal colon and/or rectal mucosa (i.e., participants must have at least part of the descending/sigmoid colon and/or rectum intact)
  • Participants must consent to a follow-up lower GI endoscopy with biopsies 4 months after their initial study lower GI endoscopy
  • Participants must consent to refrain from using aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX) inhibitors for the duration of the trial, except for cardiopreventive aspirin (less than or equal to 100 mg daily). Individuals taking such drugs may not be enrolled unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 1 month prior to enrollment. Participants will discuss with their primary care provider/local provider about the discontinuation of such medication(s) and obtain approval prior to stopping any agent
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1 (Karnofsky greater than or equal to 70%)
  • Hemoglobin greater than or equal to 10 g/dL or hematocrit greater than or equal to 30% (obtained within 30 days of study enrollment)
  • Leukocyte count greater than or equal to 3,500/microliter (obtained within 30 days of study enrollment)
  • Platelet count greater than or equal to 100,000/microliter (obtained within 30 days of study enrollment)
  • Absolute neutrophil count greater than or equal to 1,500/microliter (obtained within 30 days of study enrollment)
  • Estimated glomerular filtration rate (eGFR) (or creatinine clearance calculated using the Cockcroft-Gault equation) greater than or equal to 60 mL/min/1.73m\^2 (mL/min, within institutional limits of normal) (obtained within 30 days of study enrollment)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2 times the institutional upper limit of normal (ULN) (obtained within 30 days of study enrollment)
  • Total bilirubin less than or equal to 1.5 the ULN (obtained within 30 days of study enrollment); participants with Gilbert's disease may be enrolled with higher total bilirubin if their direct bilirubin is less than or equal to 1.5 times the ULN
  • Participants must consent to refrain from receiving adenoviral-based vaccines for the duration of the trial (16 months)
  • Participants must consent to refrain from receiving any other type of vaccination during the first 10 weeks of the trial
  • Willing and able to adhere to the prohibitions and restrictions specified in the final approved protocol
  • The effects of Nous-209 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation (16 months) and 6 months after end of study. Additionally, men who are Lynch syndrome (LS) carriers must not donate sperm for the purpose of reproduction either during the study or after the study, so as not to pass on the risk of inheriting the pathogenic gene variant to the offspring. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Prior receipt of a recombinant adenoviral or MVA vaccine, including coronavirus disease 2019 (COVID-19) adenovirus vaccines
  • Individuals with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications (such as infliximab, rituximab, adalimumab, tacrolimus) within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Pregnant or breastfeeding or planning to become pregnant within 6 months after the end of study. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with Nous-209, breastfeeding should be discontinued if the mother is treated with Nous-209
  • Participants who are receiving any other investigational agents
  • Individuals with active extra-colonic malignancy (excluding non-melanoma skin cancer)
  • Individuals with a colonic lesion larger than 15 mm with high grade dysplasia/malignancy at the time of the baseline lower GI endoscopy
  • Any serious uncontrolled and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures
  • History of organ allograft or other history of immunodeficiency
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients, or to egg proteins
  • Active infection (acute and self-limited) or human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Participants with laboratory evidence of cleared HBV and HCV infection will be permitted
  • Men attempting or planning to conceive children during the study or within 6 months after the end of the study

Where in United States

  • University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Elena M. StoffelNot yet recruiting
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Ramona M. LimNot yet recruiting
  • UT MD Anderson Cancer CenterHouston, United StatesContact: Eduardo Vilar-SanchezNot yet recruiting
  • University of Kansas Cancer CenterKansas City, United StatesContact: Ajay BansalNot yet recruiting
  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Michael J. HallNot yet recruiting

About the trial

What the trial wants to find out

This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.

The group in the trial

  • Prevention (Nous-209)Treatment being tested

    Patients receive GAd20-209-FSP IM at week 0 (day 1) followed by MVA-209-FSP IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.

    Treatment: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biopsy Procedure, Biospecimen Collection, Colonoscopy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, and Sigmoidoscopy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Clinical Trial of Nous-209 for Colorectal Pre-Cancer Immune Interception in Lynch Syndrome
Record updated
16 November 2026